AIM ImmunoTech is trading at $0.19, down 5.21%, with no clearly confirmed company-specific catalyst identified for September 25, 2026.
- A recent debt-reducing equity exchange converted approximately $400,000 of debt into 1,749,434 shares, but available coverage does not explicitly link it to the decline.
- Broader markets are modestly higher, which does not clearly explain the drop.